Cue Biopharma (CUE) - Total Assets
Based on the latest financial reports, Cue Biopharma (CUE) holds total assets worth $31.64 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cue Biopharma - Total Assets Trend (2015–2024)
This chart illustrates how Cue Biopharma's total assets have evolved over time, based on quarterly financial data. Also see how much is Cue Biopharma worth for the company's overall valuation and market capitalisation.
Cue Biopharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Cue Biopharma's total assets of $31.64 Million consist of 78.1% current assets and 21.9% non-current assets. Review Cue Biopharma balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 69.8% |
| Accounts Receivable | $945.00K | 2.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Cue Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Cue Biopharma stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cue Biopharma's current assets represent 78.1% of total assets in 2024, a decrease from 89.0% in 2015.
- Cash Position: Cash and equivalents constituted 69.8% of total assets in 2024, down from 87.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 2.9% of total assets.
Cue Biopharma Competitors by Total Assets
Key competitors of Cue Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Cue Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 2.22 | 5.36 |
| Quick Ratio | 1.66 | 2.22 | 5.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.29 Million | $20.47 Million | $71.21 Million |
Cue Biopharma - Advanced Valuation Insights
This section examines the relationship between Cue Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.12 |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | -47.7% |
| Total Assets | $32.19 Million |
| Market Capitalization | $26.56 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cue Biopharma's assets close to their book value (0.83x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Cue Biopharma's assets decreased by 47.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cue Biopharma (2015–2024)
The table below shows the annual total assets of Cue Biopharma from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $32.19 Million | -47.68% |
| 2023-12-31 | $61.53 Million | -32.59% |
| 2022-12-31 | $91.28 Million | +9.45% |
| 2021-12-31 | $83.40 Million | -16.21% |
| 2020-12-31 | $99.53 Million | +39.00% |
| 2019-12-31 | $71.61 Million | +57.85% |
| 2018-12-31 | $45.36 Million | -32.25% |
| 2017-12-31 | $66.95 Million | +311.30% |
| 2016-12-31 | $16.28 Million | +122.55% |
| 2015-12-31 | $7.31 Million | -- |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more